# Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

> **NCT00577122** · PHASE2 · COMPLETED · sponsor: **Indiana University** · enrollment: 30 (actual)

## Conditions studied

- Estrogen Receptor-negative Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Medroxyprogesterone progesterone acetate (MPA)
- **DRUG:** Medroxyprogesterone with Cyclophosphamide + Methotrexate

## Key facts

- **NCT ID:** NCT00577122
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577122, "Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00577122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*